Supplementary therapy with omega-3 polyunsaturated fatty acids improves metabolic indices in children with non-alcoholic fatty liver disease：a meta-analysis

doi:10.12114/j.issn.1007-9572.2020.00.166

Abstract

Abstract: Background　Non-alcoholic fatty liver disease （NAFLD） has become one of the chronic liver diseases in children in developed countries.With the globalization of economy，there are 155 million overweight and obese children globally with an increasing prevalence of NAFLD.However，no effective drugs for NAFLD in children have been found，and the use of drugs is still controversial.Objective　To systematically evaluate the effect of omega-3 polyunsaturated fatty acids （n-3PUFA） as an supplementary therapy on metabolic indices in children with NAFLD.Methods　Databases of PubMed，the Cochrane Library，EMBase，and Web of Science were searched from inception to May 15 2019 for RCTs about improvement in metabolic indices in NAFLD children treated with an supplementary therapy with n-3PUFA （intervention group） versus that in those with placebo as the supplementary therapy or without supplementary therapy（control group）.Meta-analysis was conducted by using RevMan 5.2.Results　A total of 6 studies were included，with a total of 378 patients.Meta-analysis showed that the intervention group showed lower mean levels of alanine aminotransferase 〔SWD=-0.34，95%CI（-0.55，-0.13）〕，aspartate aminotransferase 〔SWD=-0.27，95%CI（-0.51，-0.03）〕，triglyceride 〔SWD=-0.43，95%CI（-0.64，-0.22）〕，fasting blood glucose 〔SWD=-0.22，95%CI（-0.44，0.00）〕，fasting insulin 〔SWD=-0.38，95%CI（-0.60，-0.16）〕，homeostatic model assessment for insulin resistance （HOMA-IR）〔SWD=-0.31，95%CI（-0.52，-0.11）〕，and body mass index 〔SWD=-0.71，95%CI（-1.13，-0.30）〕，and higher mean high-density lipoprotein cholesterol 〔SWD=0.55，95%CI（0.10，1.00）〕 compared with the control group （P≤0.05）.Conclusion　The meta-analysis demonstrated that supplementary treatment with n-3PUFA may improve metabolic indices such as alanine aminotransferase，aspartate aminotransferase，triglyceride，high-density lipoprotein cholesterol，fasting blood glucose，fasting insulin，HOMA-IR，and body mass index in children with NAFLD.

Key words: Non-alcoholic fatty liver disease, Omega-3 polyunsaturated fatty acids, Child, Alanine transaminase, Aspartate aminotransferases, Meta-analysis

摘要： 背景　非酒精性脂肪肝（NAFLD）现成为发达国家儿童的慢性肝病之一，随着经济的全球化，全球有1.55亿超重和肥胖儿童，导致儿童NAFLD患病率也呈上升趋势。近年来，治疗儿童NAFLD未找到有效药物，且用药仍存在一定争议。目的　系统分析n-3多不饱和脂肪酸（n-3PUFA）补充治疗对儿童NAFLD代谢指标的影响。方法　计算机检索PubMed、the Cochrane Library、EMBase、Web of Science等数据库，检索时间为建库至2019-05-15。筛选n-3PUFA补充治疗对NAFLD患儿代谢指标影响的随机对照试验（RCT），分为干预组与对照组，采用RevMan 5.2软件进行Meta分析。结果　共纳入6篇文献，378例患儿。Meta分析结果显示，干预组NAFLD患儿丙氨酸氨基转移酶（ALT）〔标准化均数差（SWD）=-0.34，95%CI（-0.55，-0.13）〕、天冬氨酸氨基转移酶（AST）〔SWD=-0.27，95%CI（-0.51，-0.03）〕、三酰甘油（TG）〔SWD=-0.43，95%CI（-0.64，-0.22）〕、空腹血糖（FBG）〔SWD=-0.22，95%CI（-0.44，0）〕、空腹胰岛素〔SWD=-0.38，95%CI（-0.60，-0.16）〕、稳态模型胰岛素抵抗指数（HOMA-IR）〔SWD=-0.31，95%CI（-0.52，-0.11）〕、体质指数（BMI）〔SWD=-0.71，95%CI（-1.13，-0.30）〕低于对照组，高密度脂蛋白胆固醇（HDL-C）〔SWD=0.55，95%CI（0.10，1.00）〕高于对照组（P≤0.05）。结论　n-3PUFA补充治疗可改善NAFLD患儿的ALT、AST、TG、HDL-C、FBG、空腹胰岛素、HOMA-IR、BMI等代谢指标。

关键词: 非酒精性脂肪肝, n-3多不饱和脂肪酸, 儿童, 丙氨酸氨基转移酶, 天冬氨酸氨基转移酶, Meta分析

HU Chenling,SHI Xiaoyan,YAO Jia, et al. Supplementary therapy with omega-3 polyunsaturated fatty acids improves metabolic indices in children with non-alcoholic fatty liver disease：a meta-analysis[J]. Chinese General Practice, 2020, 23(20): 2558-2563. DOI: 10.12114/j.issn.1007-9572.2020.00.166.
胡臣玲,史晓燕,姚佳等. n-3多不饱和脂肪酸补充治疗改善儿童非酒精性脂肪肝代谢指标的Meta分析[J]. 中国全科医学, 2020, 23(20): 2558-2563. DOI: 10.12114/j.issn.1007-9572.2020.00.166.

References

［1］LOOMBA R，SANYAL A J.The global NAFLD epidemic［J］．Nat Rev Gastroenterol Hepatol，2013，10（11）：686-690．DOI：10.1038/nrgastro.2013.171. ［2］BYRNE C D，TARGHER G.EASL-EASD-EASO clinical practice guidelines for the management of non-alcoholic fatty liver disease：is universal screening appropriate?［J］．Diabetologia，2016，59（6）：1141-1144．DOI：10.1007/s00125-016-3910-y. ［3］AFRICA J A，NEWTON K P，SCHWIMMER J B.Lifestyle interventions including nutrition，exercise，and supplements for nonalcoholic fatty liver disease in children［J］.Dig Dis Sci，2016，61（5）：1375-1386．DOI：10.1007/s10620-016-4126-1. ［4］VILAR-GOMEZ E，MARTINEZ-PEREZ Y，CALZADILLA-BERTOT L，et al．Weight loss through lifestyle modification significantly reduces features of nonalcoholic steatohepatitis［J］．Gastroenterology，2015，149（2）：367-378.e5；quiz e14-5．DOI：10.1053/j.gastro.2015.04.005. ［5］SCORLETTI E，BYRNE C D.Omega-3 fatty acids，hepatic lipid metabolism，and nonalcoholic fatty liver disease［J］．Annu Rev Nutr，2013，33（1）：231-248．DOI：10.1146/annurev-nutr-071812-161230. ［6］OYA J，NAKAGAMI T，SASAKI S，et al．Intake of n-3 polyunsaturated fatty acids and non-alcoholic fatty liver disease：a cross-sectional study in Japanese men and women［J］．Eur J Clin Nutr，2010，64（10）：1179-1185．DOI：10.1038/ejcn.2010.139. ［7］MASTERTON G S，PLEVRIS J N，HAYES P C.Review article：omega-3 fatty acids - a promising novel therapy for non-alcoholic fatty liver disease［J］．Aliment Pharmacol Ther，2009，31（7）：679-692．DOI：10.1111/j.1365-2036.2009.04230.x. ［8］SHAMSEER L，MOHER D，CLARKE M，et al．Preferred reporting items for systematic review and meta-analysis protocols （PRISMA-P） 2015：elaboration and explanation［J］．BMJ，2015，350：g7647．DOI：10.1136/bmj.g7647. ［9］J?RGENSEN L，PALUDAN-MüLLER A S，LAURSEN D R，et al．Evaluation of the Cochrane tool for assessing risk of bias in randomized clinical trials：overview of published comments and analysis of user practice in Cochrane and non-Cochrane reviews［J］．Syst Rev，2016，5：80．DOI：10.1186/s13643-016-0259-8. ［10］BOYRAZ M，PIRGON ?，DüNDAR B，et al．Long-term treatment with n-3 polyunsaturated fatty acids as a monotherapy in children with nonalcoholic fatty liver disease［J］．J Clin Res Pediatr Endocrinol，2015，7（2）：121-127．DOI：10.4274/jcrpe.1749. ［11］DELLA CORTE C，CARPINO G，DE VITO R，et al．Docosahexanoic acid plus vitamin D treatment improves features of NAFLD in children with serum vitamin D deficiency：results from a single centre trial［J］．PLoS One，2016，11（12）：e0168216．DOI：10.1371/journal.pone.0168216. ［12］JANCZYK W，SOCHA P，LEBENSZTEJN D，et al．Omega-3 fatty acids for treatment of non-alcoholic fatty liver disease：design and rationale of randomized controlled trial［J］．BMC Pediatr，2013，13：85．DOI：10.1186/1471-2431-13-85. ［13］NOBILI V，ALISI A，DELLA CORTE C，et al．Docosahexaenoic acid for the treatment of fatty liver：randomised controlled trial in children［J］．Nutr Metab Cardiovasc Dis，2013，23（11）：1066-1070．DOI：10.1016/j.numecd.2012.10.010. ［14］PACIFICO L，BONCI E，DI MARTINO M，et al．A double-blind，placebo-controlled randomized trial to evaluate the efficacy of docosahexaenoic acid supplementation on hepatic fat and associated cardiovascular risk factors in overweight children with nonalcoholic fatty liver disease［J］．Nutr Metab Cardiovasc Dis，2015，25（8）：734-741．DOI：10.1016/j.numecd.2015.04.003. ［15］Z?HRER E，ALISI A，JAHNEL J，et al．Efficacy of docosahexaenoic acid-choline-vitamin E in paediatric NASH：a randomized controlled clinical trial［J］．Physiol Appliquee Nutr Et Metab，2017，42（9）：948-954．DOI：10.1139/apnm-2016-0689. ［16］PORTILLO P，YAVUZ S，BRIL F，et al．Role of insulin resistance and diabetes in the pathogenesis and treatment of nonalcoholic fatty liver disease［J］．Curr Hepatology Rep，2014，13（2）：159-170．DOI：10.1007/s11901-014-0229-3. ［17］PEVERILL W，POWELL L W，SKOIEN R.Evolving concepts in the pathogenesis of NASH：beyond steatosis and inflammation［J］．Int J Mol Sci，2014，15（5）：8591-8638．DOI：10.3390/ijms15058591. ［18］KIM E H，BAE J S，HAHM K B，et al．Endogenously synthesized n-3 polyunsaturated fatty acids in fat-1 mice ameliorate high-fat diet-induced non-alcoholic fatty liver disease［J］．Biochem Pharmacol，2012，84（10）：1359-1365．DOI：10.1016/j.bcp.2012.08.029. ［19］LORENTE-CEBRIáN S，BUSTOS M，MARTI A，et al．Eicosapentaenoic acid stimulates AMP-activated protein kinase and increases visfatin secretion in cultured murine adipocytes［J］．Clin Sci，2009，117（6）：243-249．DOI：10.1042/cs20090020. ［20］马蓉霞，吴葆华.儿童非酒精性脂肪肝研究进展［J］．西北国防医学杂志，2019，40（3）：195-199．DOI：10.16021/j.cnki.1007-8622.2019.03.014. MA R X，WU B H.Research progress of non-alcoholic fatty liver disease in children［J］．Medical Journal of National Defending Forces in Northwest China，2019，40（3）：195-199．DOI：10.16021/j.cnki.1007-8622.2019.03.014. ［21］KIM Y S，XUN P C，HE K.Fish consumption，long-chain omega-3 polyunsaturated fatty acid intake and risk of metabolic syndrome：a meta-analysis［J］．Nutrients，2015，7（4）：2085-2100．DOI：10.3390/nu7042085. ［22］BOYRAZ M，PIRGON ?，DüNDAR B，et al．Long-term treatment with n-3 polyunsaturated fatty acids as a monotherapy in children with nonalcoholic fatty liver disease［J］．J Clin Res Pediatr Endocrinol，2015，7（2）：121-127．DOI：10.4274/jcrpe.1749. ［23］WANG C L，LIANG L，FU J F，et al．Effect of lifestyle intervention on non-alcoholic fatty liver disease in Chinese obese children［J］．World J Gastroenterol，2008，14（10）：1598-1602．DOI：10.3748/wjg.14.1598. ［24］周雪莲，傅君芬.儿童非酒精性脂肪肝病诊断与治疗专家共识［J］．中国实用儿科杂志，2018，33（7）：487-492．DOI：10.19538/j.ek2018070602. ZHOU X L，FU J F.Expert consensus on the diagnosis and treatment of nonalcoholic fatty liver disease in children［J］．Chinese Journal of Practical Pediatrics，2018，33（7）：487-492．DOI：10.19538/j.ek2018070602.

[1]	BAI Jiaxin, CHEN Yu, ZHOU Yiheng, LIU Lidi, YANG Rong, YAO Yi, YUAN Bo, ZHANG Yonggang, LEI Yi, ZENG Rui, JIA Yu, LIAO Xiaoyang. Assessment and Treatment of Early-onset Hypertension: Position Statement of the British and Irish Hypertension Association and Its Implications for Clinical Management of Early-onset Hypertension in China [J]. Chinese General Practice, 2025, 28(30): 3741-3746.
[2]	XU Jialan, YAN Hong, WEN Jun, ZHOU Zitong, WANG Siyu. Prevalence of Potentially Inappropriate Medication in Older Adults with Cancer: a Meta-analysis [J]. Chinese General Practice, 2025, 28(30): 3815-3822.
[3]	LYU Juan, LI Yuchuan, CAI Siyu, WANG Chen. Reasons for Seeking Medical Treatment in Endocrinology Department and the Need for Non-medical Intervention in Children with Normal Height: a Qualitative Study [J]. Chinese General Practice, 2025, 28(30): 3766-3772.
[4]	ZHAO Yuqing, WANG Wei, CHEN Liyuan, YOU Huijuan, WEI Ying, WANG Qinglu, YANG Fengying. Liver Macrophage Polarisation: a New Target for Exercise Prevention and Treatment of Non-alcoholic Fatty Liver Disease [J]. Chinese General Practice, 2025, 28(27): 3456-3465.
[5]	SHAO Xiaoying, SHAO Jie, ZHU Yan, SHAO Jinling, SHANG Ling, WU Zhenlian, ZHAO Yu, ZHANG Jiacai. Analysis of the Current Status of Iron Deficiency and Factors Affecting Iron Deficiency Anemia among Children Aged 6-36 Months in Guizhou Province [J]. Chinese General Practice, 2025, 28(27): 3368-3374.
[6]	ZHANG Tianyu, YU Haibo, CHEN Fei, LI Xin, ZHANG Jiajia, ZHAN Xiaokai, SHEN Man, TANG Ran, FAN Sibin, ZHAO Fengyi, HUANG Zhongxia. Meta-analysis of the Efficacy and Safety of Systemic Treatment for POEMS Syndrome [J]. Chinese General Practice, 2025, 28(27): 3447-3455.
[7]	QUAN Jialin, ZHU Lin, SU Yu, CHEN Zekai, CHEN Ziqi, ZHANG Zhuofan. Research on the Improvement Effect of Exercise Modes on the Executive Function of Overweight or Obese Children or Adolescents: a Network Meta-analysis [J]. Chinese General Practice, 2025, 28(27): 3422-3431.
[8]	XU Yanpeng, HUANG Pe, ZHANG Pingping, LUO Yan, SHI Xiaoqi, WU Liusong, CHEN Yan, HE Zhixu. Expression of β-Adrenergic Receptors in Acute T-cell Lymphoblastic Leukemia and Its Clinical Significance [J]. Chinese General Practice, 2025, 28(27): 3391-3398.
[9]	NA Feiyang, YANG Yi, WANG Yong, WANG Yannan. Study on the Etiology of Chronic Cough in Children Aged 0-14 Years in Lanzhou from 2014 to 2023 [J]. Chinese General Practice, 2025, 28(24): 3026-3031.
[10]	JIANG Shihua, ZHU Zheng, REN Yingying, ZHU Yaolei, WANG Yue, GAO Xibin. Meta Analysis of the Prevalence and Risk Factors of Myopia in Chinese Children and Adolescents [J]. Chinese General Practice, 2025, 28(24): 3043-3052.
[11]	LI Hao, LI Jiangtao, LIU Dan, WANG Jianjun. Efficacy and Safety of Belimumab, Anifrolumab, and Telitacicept on the Treatment of Systemic Lupus Erythematosus: a Network Meta-analysis [J]. Chinese General Practice, 2025, 28(23): 2924-2933.
[12]	WANG Xiaolin, LI Qiuyue, ZHOU Yanjun, ZHANG Jinhui, LIANG Tao. Incidence and Risk of Cardiovascular Toxicity with Fruquintinib in Metastatic Colorectal Cancer: a Meta-analysis [J]. Chinese General Practice, 2025, 28(23): 2934-2940.
[13]	DU Qiongliang, LIN Bailang, GUO Honghua. Research Progress and Implications of Group Well-child Care [J]. Chinese General Practice, 2025, 28(21): 2672-2678.
[14]	LUO Jinping, SUN Jiaying, MOU Yifan, GENG Minghui, ZHANG Baoxuan, WANG Kang, YIN Wenqiang, CHEN Zhongming, MA Dongping. Quantitative Evaluation of China's Pediatric Drug Policies Based on Policy Modeling Consistency Index Model [J]. Chinese General Practice, 2025, 28(21): 2652-2660.
[15]	MA Panpan, WANG Sijing, YOU Na, DING Dafa, LU Yibing. Efficacy and Safety of Danuglipron and Orforglipron in the Treatment of Type 2 Diabetes Mellitus: a Meta-analysis [J]. Chinese General Practice, 2025, 28(21): 2679-2685.